• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, October 27, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Insilico Medicine gets $255 million to boost AI-powered R&D, announces a collaboration

Bioengineer by Bioengineer
September 6, 2025
in Chemistry
Reading Time: 3 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

It also announced that it entered into a collaboration with Teva Branded Pharmaceutical Products R&D, Inc. to utilize Insilico’s generative machine learning technology and proprietary PandaOmics Drug Discovery Platform, which aims at identifying novel therapeutic targets implicated in a variety of diseases.

As a pioneer and leader in the industry, Insilico Medicine has built a strong drug discovery and drug development team, a broad distributed discovery partner network, and initiated multiple internal therapeutic programs. Previously, the company published a range of papers on generative chemistry and achieved multiple milestones with the pharmaceutical industry partners. The company demonstrated the first case of AI identifying a novel target for a major pulmonary disease, generating novel molecules for that novel target, and completing the preclinical experiments required to nominate a preclinical candidate in under 18 months. Insilico Medicine also developed the AI-powered drug discovery platform consisting of PandaOmics AI-powered novel target discovery engine, Chemistry42 deep generative reinforcement learning system allowing for de-novo design of novel molecules with the desired properties that do not exist in the known chemical space, and InClinico, which predicts clinical trial outcomes.

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine said, “The artificial intelligence technologies we invented are now demonstrating impressive results in both biology and chemistry delivering valuable and absolutely novel therapeutic assets with high probability of clinical success. We are pleased and proud to have gained the recognition and investment from some of the world’s most reputable investors with strong expertise in the biopharmaceutical industry. With their support, we will continue to innovate and bring revolutionary solutions to the pharmaceutical industry.”

Insilico Medicine is making its technologies available for licensing for the leading pharmaceutical and biotechnology companies looking to gain a head start in AI and accelerate their drug discovery programs. It has collaborated with first-in-class biopharmaceutical companies, including Pfizer, Astellas, Johnson & Johnson, Taisho, and many others, with multiple partners reaching major milestones. Insilico Medicine also exclusively partnered with the main innovative sustainable agriculture company, Syngenta, on the discovery of novel molecules for sustainable regenerative farming. Since the launch of Chemistry42 in September 2020, 7 out of the top 30 pharmaceutical companies deployed its software, including Merck KGaA and UCB. Insilico Medicine also built a drug discovery team and platform in China and started multiple therapeutic programs targeting novel, difficult, and previously undruggable targets.

###

About Insilico Medicine

Insilico Medicine develops artificial intelligence systems that utilize deep generative models, reinforcement learning (RL), transformers, and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AI platform (http://www.insilico.com/platform/) and developing its own pipeline of preclinical programs. It has demonstrated the ability to identify the novel target for a major disease, generate and validate novel molecules with the desired properties for that target and nominate a preclinical candidate in under 18 months. Since its inception in 2014, Insilico Medicine has raised over $310 million from expert pharmaceutical, and technology investors, and received multiple industry awards. Insilico Medicine has also published over 130 peer-reviewed papers and has applied for over 30 patents. For more information, please visit http://www.insilico.com.

Media Contact
Polly Firs
[email protected]

Tags: AgingBiochemistryBiodiversityBioinformaticsBiotechnologyBusiness/EconomicsCollaborationGenesGerontologyGroup Organization
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Bezos Earth Fund Awards $2M to UC Davis and American Heart Association to Pioneer AI-Designed Foods

October 24, 2025
Organocatalytic Intramolecular Macrocyclization of Quinone Methylidenes with Alcohols Achieves Enantio-, Atropo-, and Diastereoselectivity

Organocatalytic Intramolecular Macrocyclization of Quinone Methylidenes with Alcohols Achieves Enantio-, Atropo-, and Diastereoselectivity

October 24, 2025

Breakthrough Discovery of Elusive Solar Waves That May Energize the Sun’s Corona

October 24, 2025

From Wastewater to Fertile Ground: Chinese Researchers Achieve Dual Breakthroughs in Phosphorus Recycling

October 23, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1285 shares
    Share 513 Tweet 321
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    196 shares
    Share 78 Tweet 49
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    134 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Fluid Strategies in Preterm Infants with PDA

Unlocking Henna’s Healing Power: A Breakthrough Chemical from Lawsonia inermis Fights Fibrosis

ACHO: Enhancing Treatment Adherence through Digital Care

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.